Proqr Therapeutics N V (PRQR)

04:35 AM

RNA Editing Market Top Companies StudyProQR Therapeutics NV, - openPR

04:35 AM

04:19 AM

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat

04:19 AM

Nov 20, 2024

ProQR Therapeutics NV (MEX:PRQR) 50-Day SMA : MXN35.82 (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

ProQR Therapeutics NV (FRA:0PQ) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

ProQR Therapeutics NV (FRA:0PQ) 3-Year EBITDA Growth Rate : 31.80% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 20, 2024

ProQR Therapeutics NV (FRA:0PQ) 3-Year Book Growth Rate : -26.20% (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 14, 2024

ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World

Nov 14, 2024

Nov 13, 2024

What is Chardan Capital's Forecast for PRQR FY2024 Earnings? - MarketBeat

Nov 13, 2024

Nov 08, 2024

ProQR: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 08, 2024

Nov 08, 2024

ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright - MarketBeat

Nov 08, 2024

Nov 07, 2024

ProQR Therapeutics NV earnings beat, revenue fell short of estimates - Investing.com

Nov 07, 2024

Nov 07, 2024

ProQR Therapeutics NV earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK

Nov 07, 2024

Nov 07, 2024

PRQRProQR Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Nov 07, 2024

Nov 07, 2024

ProQR Announces Third Quarter 2024 Operating and Financial Results - GlobeNewswire

Nov 07, 2024

Nov 06, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat

Nov 06, 2024

Oct 30, 2024

Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN

Oct 30, 2024

Oct 29, 2024

ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow

Oct 29, 2024

Oct 29, 2024

ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat

Oct 29, 2024

Oct 26, 2024

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire

Oct 26, 2024

Oct 25, 2024

ProQR Announces Major Share Offering Agreement - TipRanks

Oct 25, 2024

Oct 23, 2024

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump - Simply Wall St

Oct 23, 2024

Oct 23, 2024

ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in - XM

Oct 23, 2024

Oct 23, 2024

Form 424B5 ProQR Therapeutics N.V. - StreetInsider.com

Oct 23, 2024

Oct 23, 2024

ProQR launches public offering to fund RNA therapy research - Investing.com India

Oct 23, 2024

Oct 22, 2024

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - StockTitan

Oct 22, 2024

Oct 22, 2024

ProQR Therapeutics announces public offering of ordinary shares - MSN

Oct 22, 2024

Oct 22, 2024

ProQR launches public offering to fund RNA therapy research By Investing.com - Investing.com UK

Oct 22, 2024

Oct 22, 2024

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewswire

Oct 22, 2024

Oct 20, 2024

ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance

Oct 20, 2024

Oct 16, 2024

RNA-Editing Stocks Soar by Record on Wave Life’s Trial Data - Yahoo Finance

Oct 16, 2024

Oct 14, 2024

Proqr Therapeutics RNA editing technology counteracts cholestatic disease - BioWorld Online

Oct 14, 2024

Oct 07, 2024

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times

Oct 07, 2024

Oct 07, 2024

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewswire Inc.

Oct 07, 2024

Oct 05, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World

Oct 05, 2024

Oct 05, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat

Oct 05, 2024

Oct 04, 2024

Investing in ProQR Therapeutics N.V (PRQR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News

Oct 04, 2024

Oct 02, 2024

Best Momentum Stocks to Buy for October 2nd - Yahoo Finance

Oct 02, 2024

Sep 30, 2024

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India

Sep 30, 2024

Sep 30, 2024

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase By Investing.com - Investing.com South Africa

Sep 30, 2024

Sep 27, 2024

ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat

Sep 27, 2024

Sep 27, 2024

ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $1.95 - Defense World

Sep 27, 2024

Sep 26, 2024

ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle

Sep 26, 2024

Sep 26, 2024

Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex

Sep 26, 2024

Sep 19, 2024

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat

Sep 19, 2024

Sep 19, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World

Sep 19, 2024

Sep 10, 2024

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire

Sep 10, 2024

Sep 10, 2024

ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat

Sep 10, 2024

Sep 10, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World

Sep 10, 2024